November 24, 2021 06:56 AM ESTUpdated 10:25 AM
Pharma
Coronavirus

Eu­rope changes its tune on Covid-19 vac­cine IP, ad­vo­cat­ing now for a 'tar­get­ed waiver'

Zachary Brennan

Senior Editor

Just a month af­ter it seemed like ne­go­ti­a­tions were get­ting nowhere fast on waiv­ing the in­tel­lec­tu­al prop­er­ty around Covid-19 vac­cines ahead of a De­cem­ber …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times